Center for Molecular Discovery participation with NExT program

Dr. Larry Sklar, Director of UNMCMD

UNM Comprehensive Cancer Center
June 9, 2016

The University of New Mexico Health Sciences Center has joined a national network of scientists on the leading edge of drug discovery and development in the fight against cancer, centered at the Frederick National Laboratory for Cancer Research.

The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with world-class expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. The University of New Mexico received a $375,000 subcontract for infrastructure and project costs associated with its participation in the consortium.

“The NExT program consolidates programs in [drug] discovery, development and clinical trials,” says Larry Sklar, PhD. “It represents an integrated approach in cancer therapeutics.” The new Center of Excellence, and Sklar’s leadership of it, will help UNM to integrate its own drug development pipeline. “We’ve been asked to form the team which links clinical trials and discovery,” he says.

Sklar plays many roles at UNM Health Sciences Center, which allows him to create and work on projects with far-reaching impact. A Distinguished Professor of Pathology, Sklar serves as Director of the Center for Molecular Discovery. He co-leads the Cancer Therapeutics Research Program at the UNM Comprehensive Cancer Center. And, he directs the Drug Rescue, Repurposing and Repositioning Network at the UNM Clinical and Translational Science Center. Sklar will direct the new Chemical Biology Consortium Center of Excellence at UNM. All of these centers within UNM HSC share methods, technologies and resources.

Read more.

University of New Mexico flow cytometry research center